[breadcrumb_custom]

Dyne Therapeutics Inc (NASDAQ: DYN) Is Under Pressure Due To Weak Fundamental Momentum.

In the last trading session, 1.02 million Dyne Therapeutics Inc (NASDAQ:DYN) shares changed hands as the company’s beta touched 0.89. With the company’s per share price at $24.01 changed hands at $1.28 or 5.63% during last session, the market valuation stood at $1.47B. DYN’s last price was a discount, traded about -6.21% off its 52-week high of $25.50. The share price had its 52-week low at $6.40, which suggests the last value was 73.34% up since then. When we look at Dyne Therapeutics Inc’s average trading volume, we note the 10-day average is 1.22 million shares, with the 3-month average coming to 0.54.

Dyne Therapeutics Inc (NASDAQ:DYN) trade information

Instantly DYN was in green as seen at the end of in last trading. With action 14.12%, the performance over the past five days has been green. The jump to weekly highs of 24.92 added 5.63% to the stock’s daily price. The company’s shares are showing year-to-date upside of 80.53%, with the 5-day performance at 14.12% in the green. However, in the 30-day time frame, Dyne Therapeutics Inc (NASDAQ:DYN) is 38.47% up. Looking at the short shares, we see there were 8.55 million shares sold at short interest cover period of 2.28 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Dyne Therapeutics Inc (DYN) estimates and forecasts

Data shows that the Dyne Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 119.87% over the past 6 months, a -15.79% in annual growth rate that is considerably lower than the industry average of 11.60%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -135.08%. The 2024 estimates are for Dyne Therapeutics Inc earnings to decrease by -16.64%.

DYN Dividends

Dyne Therapeutics Inc is expected to release its next quarterly earnings report between February 29 and March 04.

Dyne Therapeutics Inc (NASDAQ:DYN)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 1.12% of Dyne Therapeutics Inc shares while 88.52% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 89.52%. There are 88.52% institutions holding the Dyne Therapeutics Inc stock share, with Atlas Venture Life Science Advisors, LLC the top institutional holder. As of Jun 29, 2023, the company held 16.20% of the shares, roughly 9.89 million DYN shares worth $111.21 million.

MPM Asset Management, LLC holds the second largest percentage of outstanding shares, with 8.11% or 4.95 million shares worth $55.7 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. With 1.45 million shares estimated at $16.35 million under it, the former controlled 2.38% of total outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held about 1.62% of the shares, roughly 0.99 million shares worth around $11.26 million.

On Key

Related Posts